ClinicalTrials.gg
CompletedNCT04753606ROSEUpdated Jul 12, 2024Results posted

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

A Phase 2 interventional study of Obicetrapib in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 19 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-12.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 42 under way, 11 of them phase 3. Hypercholesterolemia · United States.

Enrollment
173rd of 347
120 · median 120
Started
2021
with 15 others
Phase 2
66 of 379
5 open now
Registered
300th of 379
by date

Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 173rd largest by enrollment of the 347 interventional ones that give a count, is one of 16 that started in 2021, is one of 66 in phase 2, and was the 300th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 379 studies in Hypercholesterolemia with a site in United States, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Read the detailed description

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy. The screening period for this study will take up to 2-weeks. Afterwards patients will be randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up and a 15-week PK follow-up.

03

Conditions studied

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia

Browse trials for

Keywords

  • obicetrapib
  • statin
  • LDL-C
  • cholesterol
  • atherosclerosis
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 120 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LDL-C > 70 mg/dL and TG \< 400 mg/dL,
  • Treated with a high-intensity statin therapy

Exclusion criteria

Exclusion Criteria:

  • > 40 kg/m
  • Significant cardiovascular disease
  • > 10%
  • Uncontrolled hypertension
  • Active muscle disease
  • \< 60 ml/min
  • Hepatic dysfunction
  • Anemia
  • History of
  • Alcohol abuse
  • Treatment with product
  • Treatment with PCSK9
  • condition
  • Known CETP inhibitor allergy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    once-daily placebo

    Drug: Obicetrapib

  • Experimental
    obicetrapib 5 mg

    once-daily obicetrapib

    Drug: Obicetrapib

  • Experimental
    obicetrapib 10 mg

    once-daily obicetrapib

    Drug: Obicetrapib

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group.LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

    Time frame: 8-weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

    Time frame: 8-Weeks

  3. LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    LS mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

    Time frame: 8-Weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 8-Weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 8-Weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    LS Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 8-Weeks

Secondary outcomes

  1. Mean Percent Change in Apolipoprotein B (ApoB)

    Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-Weeks

  2. Median Percent Change in Apolipoprotein B (ApoB)

    Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-Week

  3. LS Mean Percent Change in Apolipoprotein B (ApoB)

    Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-Weeks

  4. Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8-weeks

  5. Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8-Weeks

  6. LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8-Weeks

  7. Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-weeks

  8. Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-Weeks

  9. LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    LS mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8-Weeks

08

Results

Posted Jun 11, 2024

Participant flow

195 participants were screened; out of 195, 120 participants were randomized.

Participant flow — Overall Study
MilestonePlaceboObicetrapib 5 mgObicetrapib 10 mg
Started404040
Completed394040
Not completed100
Withdrew: Adverse event100

Outcome measures

PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group.LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

Time frame:
8-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]-5.48 ± 23.357-37.97 ± 27.526-43.35 ± 19.369
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -32.96 · 95% CI -44.03 to -21.90mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -39.18 · 95% CI -50.21 to -28.15mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

Time frame:
8-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]0 (-57.9 to 40.3)-42.90 (-81.9 to 72.4)-45.65 (-78.0 to 26.2)
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -32.96 · 95% CI -44.03 to -21.90mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -39.18 · 95% CI -50.21 to -28.15mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryLS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

LS mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),

Time frame:
8-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]-5.00 ± 3.502-37.97 ± 3.491-44.18 ± 3.461
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -32.96 · 95% CI -44.03 to -21.90mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -39.18 · 95% CI -50.21 to -28.15mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
8-Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]-7.11 ± 20.773-35.98 ± 25.469-46.06 ± 19.393
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -28.94 · 95% CI -38.14 to -19.74
  • Placebo vs Obicetrapib 10 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -40.07 · 95% CI -49.16 to -30.97
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
8-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]-6.50 (-53.9 to 31.6)-41.45 (-71.2 to 62.3)-50.75 (-76.9 to 15.6)
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -28.94 · 95% CI -38.14 to -19.74
  • Placebo vs Obicetrapib 10 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -40.07 · 95% CI -49.16 to -30.97
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

LS Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
8-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]-6.70 ± 3.263-35.65 ± 3.305-46.77 ± 3.225
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -28.94 · 95% CI -38.14 to -19.74
  • Placebo vs Obicetrapib 10 mg · ANCOVA · p = <.0001 · Least squares (ls) means: -40.07 · 95% CI -49.16 to -30.97
SecondaryMean Percent Change in Apolipoprotein B (ApoB)

Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Mean Percent Change in Apolipoprotein B (ApoB)-4.67 ± 17.687-22.62 ± 21.882-27.19 ± 15.329
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -18.26 · 95% CI -25.51 to -11.02mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -23.99 · 95% CI -31.22 to -16.76mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein B (ApoB)

Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-Week
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Median Percent Change in Apolipoprotein B (ApoB)-2.60 (-50.0 to 28.4)-24.40 (-58.5 to 47.4)-29.75 (-58.4 to 13.0)
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -18.26 · 95% CI -25.51 to -11.02mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -23.99 · 95% CI -31.22 to -16.76mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein B (ApoB)

Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
LS Mean Percent Change in Apolipoprotein B (ApoB)-4.13 ± 2.593-22.40 ± 2.582-28.12 ± 2.564
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -18.26 · 95% CI -25.51 to -11.02mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -23.99 · 95% CI -31.22 to -16.76mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-4.22 ± 20.440-34.28 ± 25.623-39.25 ± 17.625
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -30.54 · 95% CI -39.46 to -21.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -36.03 · 95% CI -44.92 to -27.14mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-3.50 (-50.3 to 48.4)-38.90 (-65.6 to 66.3)-44.40 (-70.2 to 22.5)
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -30.54 · 95% CI -39.46 to -21.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -36.03 · 95% CI -44.92 to -27.14mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-3.83 ± 3.191-34.37 ± 3.179-39.86 ± 3.153
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -30.54 · 95% CI -39.46 to -21.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -36.03 · 95% CI -44.92 to -27.14mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)-6.62 ± 12.436123.92 ± 57.671156.41 ± 52.165
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 129.27 · 95% CI 110.78 to 147.77mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 164.33 · 95% CI 145.90 to 182.76mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)-4.90 (-30.3 to 28.6)135.40 (-26.4 to 212.9)164.95 (55.1 to 286.3)
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 129.27 · 95% CI 110.78 to 147.77mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 164.33 · 95% CI 145.90 to 182.76mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

LS mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlaceboObicetrapib 5 mgObicetrapib 10 mg
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)-6.98 ± 6.620122.29 ± 6.585157.35 ± 6.538
Statistical analysis
  • Placebo vs Obicetrapib 5 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 129.27 · 95% CI 110.78 to 147.77mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs Obicetrapib 10 mg · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: 164.33 · 95% CI 145.90 to 182.76mixed model for repeated measures (MMRM) with missing at random assumption

Adverse events

Collected over From first dose of study drug through week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/40 (0%)2/40 (5%)17/40 (42.5%)
Obicetrapib 5 mg0/40 (0%)0/40 (0%)15/40 (37.5%)
Obicetrapib 10 mg0/40 (0%)0/40 (0%)8/40 (20%)
Most frequent serious events
Most frequent serious events
EventPlaceboObicetrapib 5 mgObicetrapib 10 mg
Transient ischemic attackNervous system disorders1/400/400/40
COVID-19 pneumoniaInfections and infestations1/400/400/40
Most frequent other events
Showing 10 of 53
Most frequent other events
EventPlaceboObicetrapib 5 mgObicetrapib 10 mg
NauseaGastrointestinal disorders2/401/400/40
Muscle spasmsMusculoskeletal and connective tissue disorders2/400/400/40
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/400/400/40
FatigueGeneral disorders2/402/401/40
Type 2 diabetes mellitusMetabolism and nutrition disorders0/402/400/40
HypertensionVascular disorders0/402/400/40
Pelvic PainReproductive system and breast disorders1/400/400/40
Abdominal distensionGastrointestinal disorders1/400/400/40
VomitingGastrointestinal disorders1/400/400/40
Perineal abscessInfections and infestations1/400/400/40

Baseline characteristics

Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.

Age, Continuous
Age, Continuous(years)PlaceboObicetrapib 5 mgObicetrapib 10 mgTotal
Mean61.3 ± 8.7761.1 ± 8.1362.9 ± 8.4861.8 ± 8.43
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboObicetrapib 5 mgObicetrapib 10 mgTotal
Female21171553
Male19232567
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboObicetrapib 5 mgObicetrapib 10 mgTotal
Hispanic or Latino35614
Not Hispanic or Latino373534106
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboObicetrapib 5 mgObicetrapib 10 mgTotal
American Indian or Alaska Native0000
Asian1056
Native Hawaiian or Other Pacific Islander0000
Black or African American710522
White32303092
More than one race0000
Unknown or Not Reported0000
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL))PlaceboObicetrapib 5 mgObicetrapib 10 mgTotal
Mean98.6 ± 31.0999.2 ± 30.9594.2 ± 31.1497.33 ± 31.06
09

Study locations

19 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • National Research Institute - Wilshire
    Los Angeles, California 90057, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34474, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
  • Diabetes and Endocrinology Consultants, P.C.
    Morehead City, North Carolina 28557, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58104, United States
  • Metabolic and Atherosclerosis Research Center
    Cincinnati, Ohio 45227, United States
  • Summit Research Group, LLC
    Munroe Falls, Ohio 44262, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Juno Research, LL
    Houston, Texas 77040, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
10

References and documents

Publications

  • Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, Alp NJ, Davidson MH. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 Aug;28(8):1672-1678. doi: 10.1038/s41591-022-01936-7. Epub 2022 Aug 11. PubMed 35953719 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2021, 3 months.

Results were first posted in Jun 2024, 3 years after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 15, 2021
StartActual
Feb 18, 2021
Primary completionActual
May 24, 2021
CompletionActual
Aug 30, 2021
Results first posted
Jun 11, 2024
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04753606
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Feb 18, 2021
Primary completion
May 24, 2021
Completion
Aug 30, 2021
Results posted
Jun 11, 2024
Last update
Jul 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion